MicroRNA-101 has a suppressive role in osteosarcoma cells through the targeting of c-FOS
Authors: Zili Wang
Rongzhen He
Song Wu
Y U Wei
Hansong Xia
Journal: Experimental and Therapeutic Medicine (2016)
Discipline: CLINICAL MEDICINE
Keywords: invasion; microRNA-101; migration; osteosarcoma; proliferation.
Affiliations: Department of Orthopaedic Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China.

Abstract:  MicroRNAs (miRs) have been implicated in the development and progression of osteosarcoma (OS). However, the underlying mechanism of miR-101 in regulating of the proliferation, migration and invasion of OS cells remains to be elucidated. In the present study, reverse transcription-quantitative polymerase chain reaction data revealed that miR-101 was frequently downregulated in the tissue samples of 12 patients with OS compared with their matched adjacent non-tumor tissues. Furthermore, miR-101 was significantly downregulated in three common OS cell lines, Saos-2, MG63 and U2OS, compared with the human osteoblast cell line, hFOB1.19 (P&lt;0.01). A luciferase reporter assay was also performed and identified c-FOS as a novel target of miR-101 in U2OS cells; overexpression of miR-101 significantly suppressed the protein expression levels of c-FOS, while knockdown of miR-101 significantly enhanced the formers' expression levels in U2OS cells (P&lt;0.01). Independent inhibition of c-FOS and overexpression of miR-101 expression levels significantly suppressed U2OS cell proliferation, migration and invasion (P&lt;0.01). However, overexpression of c-FOS reversed the inhibitory effect of miR-101 upregulation on proliferation, migration and invasion of U2OS cells, suggesting that miR-101 acts as a tumor suppressor in OS cells via targeting of c-FOS. Thus, we propose that the miR-101/c-FOS axis may be a potential therapeutic target for OS. 

Retracted: Yes

PubPeer comments:
 Fig 5A.  Wound healing assay to determine the migratory capacity of U2OS cells transfected with miR-101 mimics or c-FOS siRNA, or co-transfected with miRu2011101 mimics and cu2011FOS plasmid .  For comparison, Figure 4 from [Yang et al (2016)] .  Wound healing assay was performed to determine the migratory capacity of PANC-1 cells transfected with pcDNA3.1-PREX2 plasmid or PREX2-specific small interfering RNA. As control, non-transfected PANC-1 cells were used .  Surprisingly many repeated panels. , 
 *[lower]* Fig 5B.  Transwell assay to determine the invasive capacity of U2OS cells transfected with miRu2011101 mimics or cu2011FOS siRNA, or cou2011transfected with miRu2011101 mimics and cu2011FOS plasmid. Magnification, x100. Control: untransfected U2OS cells . *[upper]* Figs 4 C D and 5C from [Yang et al (2016)] .  Transwell assays were conducted to examine the cell invasion capacities ofA549 cells transfected with (C) miR-133b mimics and (D) FSCN1 plasmids. Non-transfected A549 cells were used as control ....  Transwell assay were conducted to examine the cell migration and invasion in each group .  --------------------------------------- Update: Fig 7 from [Wang et al (2014)] .  , 
 An editor[ retraction] on July 9th, 2021: Following the publication of this paper, it was drawn to the Editors attention by a concerned reader that certain of the scratchu2011wound assay data shown in Fig. 5A and Transwell cell migration data shown in Fig. 5B were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere, or were already under consideration for publication, prior to its submission to Experimental and Therapeutic Medicine, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive any reply. The Editor apologizes to the readership for any inconvenience caused. ,